Legal status · Australia
Is BI 3034701 legal in Australia?
No. BI 3034701 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
BI 3034701 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Evidence level | Preliminary (research strength: Preliminary) |
| Reviewed | Sep 2026 |
Classification and note come from the BI 3034701 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
BI 3034701 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What BI 3034701 is
Boehringer Ingelheim's first-in-class triple agonist that swaps glucagon for the NPY2 (PYY-type) satiety receptor, entering Phase 2 in July 2026 with no efficacy data yet.
Most triple agonists combine GLP-1, GIP and glucagon. BI 3034701 instead adds neuropeptide Y2 receptor activation, reproducing the satiety signal of PYY, a gut hormone released after meals, which is a way to add fullness without adding glucagon.
Mechanism: Agonism of GLP-1, GIP and NPY2 receptors; the NPY2 component reproduces PYY-mediated appetite suppression.
Regulatory history: Investigational; Phase 2
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for BI 3034701 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
BI 3034701 in other countries
Frequently asked questions
Is BI 3034701 legal in Australia?
No. BI 3034701 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy BI 3034701 in Australia?
No approved product exists to buy. In Australia BI 3034701 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is BI 3034701 TGA approved?
No. In Australia BI 3034701 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational; Phase 2. Evidence level: Preliminary.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for BI 3034701 live on its compound profile.
BI 3034701 profileThis page is general information about the regulatory status of BI 3034701 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.